Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VIR
stocks logo

VIR

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
2.72M
-11.48%
-0.718
-29.58%
2.72M
+14.37%
-0.709
-54.53%
2.72M
-78%
-0.706
-7.12%
Estimates Revision
The market is revising Downward the revenue expectations for Vir Biotechnology, Inc. (VIR) for FY2025, with the revenue forecasts being adjusted by -31.22% over the past three months. During the same period, the stock price has changed by 0.00%.
Revenue Estimates for FY2025
Revise Downward
down Image
-31.22%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.19%
In Past 3 Month
Stock Price
No Change
down Image
0.00%
In Past 3 Month
9 Analyst Rating
up Image0
Wall Street analysts forecast VIR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VIR is 18.14 USD with a low forecast of 12.00 USD and a high forecast of 31.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
2 Hold
0 Sell
Strong Buy
up Image0
Current: 5.500
sliders
Low
12.00
Averages
18.14
High
31.00
up Image0
Current: 5.500
sliders
Low
12.00
Averages
18.14
High
31.00
Raymond James
initiated
$12
2025-07-11
Reason
Raymond James
Price Target
$12
2025-07-11
initiated
Reason
Raymond James initiated coverage of Vir Biotechnology with an Outperform rating and $12 price target.
Raymond James
Sean McCutcheon
Outperform
initiated
$12
2025-07-11
Reason
Raymond James
Sean McCutcheon
Price Target
$12
2025-07-11
initiated
Outperform
Reason
Raymond James analyst Sean McCutcheon initiated coverage of Vir Biotechnology with an Outperform rating and $12 price target. Vir's VIR-5500 shows "compelling" early Phase 1 data in heavily treated metastatic castration-resistant prostate cancer patients, and VIR-5500 is well-positioned to capture share in the large and growing mCRPC market, the analyst tells investors in a research note. The firm's constructive view is balanced by competitive headwinds in prostate cancer, as well as the company's high burn rate and need for additional financing to bring VIR-5500 through pivotal studies.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$110 -> $15
2025-05-20
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$110 -> $15
2025-05-20
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Vir Biotechnology to $15 from $110 and keeps a Buy rating on the shares. The company's updated 24-week off-treatment data from the Phase 2 program did not meet functional cure thresholds that would be needed to support a Phase 3 investment in the absence of a global partner in chronic hepatitis B virus, the analyst tells investors in a research note. The firm believes chronic hepatitis delta virus infection is now Vir's clear lead value driver in hepatitis.
Goldman Sachs
Paul Choi
Strong Buy
Maintains
$28 → $21
2025-04-17
Reason
Goldman Sachs
Paul Choi
Price Target
$28 → $21
2025-04-17
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$110
2025-02-28
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$110
2025-02-28
Reiterates
Strong Buy
Reason
Barclays
Gena Wang
Buy
Maintains
$26 → $31
2025-02-28
Reason
Barclays
Gena Wang
Price Target
$26 → $31
2025-02-28
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Vir Biotechnology Inc (VIR.O) is -1.87, compared to its 5-year average forward P/E of -7.25. For a more detailed relative valuation and DCF analysis to assess Vir Biotechnology Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.25
Current PE
-1.87
Overvalued PE
9.64
Undervalued PE
-24.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.50
Current EV/EBITDA
-0.12
Overvalued EV/EBITDA
9.01
Undervalued EV/EBITDA
-16.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Overvalued
5Y Average PS
23.11
Current PS
69.03
Overvalued PS
40.18
Undervalued PS
6.05

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders areSelling! The selling amount has increased 594.82% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 3690.48% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 594.82% over the last month.
Sold
Bought

VIR News & Events

Events Timeline

(ET)
2025-05-09
06:07:50
Vir Biotechnology reports data from MARCH Phase 2 clinical study
select
2025-05-07 (ET)
2025-05-07
17:04:26
Vir Biotechnology reports Q1 EPS (88c), consensus (84c)
select
2025-03-13 (ET)
2025-03-13
08:08:46
Vir Biotechnology enrolls first patient in ECLIPSE program
select
Sign Up For More Events
Sign Up For More Events

News

Preview
2.0
07-10NASDAQ.COM
$VIR stock is up 13% today. Here's what we see in our data.

  • Stock Performance: $VIR stock has increased by 13% today with a trading volume of approximately $15 million, while insiders have sold shares 12 times in the last six months without any purchases.

  • Analyst Ratings and Institutional Activity: Five firms have issued buy ratings for $VIR, with no sell ratings, and recent institutional activity shows 117 investors added shares while 97 reduced their positions.

Preview
1.0
05-21Newsfilter
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

  • Fireside Chat Announcement: Vir Biotechnology's CEO Marianne De Backer and EVP Mika Kakefuda Derynck will participate in a virtual fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit on May 27, with a live webcast available on their website.

  • Company Overview: Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing treatments for serious infectious diseases and cancer, with ongoing clinical programs and a preclinical portfolio targeting various health issues.

Preview
6.0
05-12Benzinga
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday

  • Analyst Rating Changes: Several Wall Street analysts have adjusted their price targets and ratings for various companies, including Guggenheim lowering Intellia Therapeutics' target from $55 to $45 while maintaining a Buy rating, and Goldman Sachs cutting Warner Music Group's target from $35 to $28 and downgrading it from Buy to Neutral.

  • Upgrades and Downgrades: Notable upgrades include JP Morgan raising Teva Pharmaceutical's target from $21 to $23 and upgrading it from Neutral to Overweight, while Jefferies increased Marriott International's target from $226 to $303 and upgraded it from Hold to Buy.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Vir Biotechnology Inc (VIR) stock price today?

The current price of VIR is 5.5 USD — it has increased 1.66 % in the last trading day.

arrow icon

What is Vir Biotechnology Inc (VIR)'s business?

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.

arrow icon

What is the price predicton of VIR Stock?

Wall Street analysts forecast VIR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VIR is 18.14 USD with a low forecast of 12.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Vir Biotechnology Inc (VIR)'s revenue for the last quarter?

Vir Biotechnology Inc revenue for the last quarter amounts to 3.03M USD, decreased -94.62 % YoY.

arrow icon

What is Vir Biotechnology Inc (VIR)'s earnings per share (EPS) for the last quarter?

Vir Biotechnology Inc. EPS for the last quarter amounts to -0.88 USD, increased 83.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Vir Biotechnology Inc (VIR)'s fundamentals?

The market is revising Downward the revenue expectations for Vir Biotechnology, Inc. (VIR) for FY2025, with the revenue forecasts being adjusted by -31.22% over the past three months. During the same period, the stock price has changed by 0.00%.
arrow icon

How many employees does Vir Biotechnology Inc (VIR). have?

Vir Biotechnology Inc (VIR) has 408 emplpoyees as of July 17 2025.

arrow icon

What is Vir Biotechnology Inc (VIR) market cap?

Today VIR has the market capitalization of 747.87M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free